Purpose: To review the literature on prevention of intravascular catheter-related infections.
S everal million intravascular catheters are purchased each year by U.S. hospitals and clinics. Use of these devices place large numbers of patients at risk for catheter-related bloodstream infection. Most serious infections are associated with central venous catheters rather than small peripheral catheters (1); this is particularly evident in intensive care units (ICUs). According to a computer model of utilization of ICU beds based on American Hospital Association data (Halpern N. Personal communication), there were approximately 31 million patientdays annually in ICUs in the United States over the past 6 years. On the basis of data from the Centers for Disease Control and Prevention (2), the risk for exposure to these devices per ICU day was 48%, leading to approximately 15 million central linedays per year in ICUs. With an average of 5.3 central line-associated bloodstream infections per 1000 catheter-days in ICUs (2) , approximately 16 000 central line-associated bloodstream infections occurred in ICUs in the United States each year. The attributable mortality has ranged from 12% to 25% in prospective studies (1, 3) but was an average of 3% in a meta-analysis (4). The attributable cost per infection is $3700 to $29 000 (3, 5) . Therefore, in U.S. ICUs, approximately 500 to 4000 patients die annually of central venous catheterrelated bloodstream infections. The annual cost of caring for patients with central line-associated bloodstream infections is $60 million to $460 million. A significant proportion of non-ICU patients have central venous catheters (for example, patients on hematology-oncology wards), and many patients are discharged with central venous catheters in place. These patients are also at risk for serious catheterrelated infections.
The microbes that colonize catheter hubs and the skin surrounding the insertion site are the source of most catheter-related bloodstream infections (6 -8) . Therefore, successful preventive strategies must reduce colonization of the insertion site and hubs or minimize microbial spread extraluminally from the skin or intraluminally from the hubs toward the catheter tip lying in the bloodstream (Figure) . Inhibiting the adherence and growth of pathogens that reach the intravascular segment of the catheter would also be ideal.
Attention to simple and practical interventions reduces the risk for intravascular catheter-related bloodstream infections (9 -11) . This review updates the expanding body of literature on the prevention of these infections.
Methods
Clinical studies of intravascular catheters were identified by searching the MEDLINE database for articles published from January 1966 to February 1999. The proceedings of the Infectious Diseases Society of America from 1994 through 1999, the Interscience Conference on Antimicrobial Agents and Chemotherapy from 1984 through 1999, and the proceedings of the Society for Healthcare Epidemiology of America Annual Meetings from 1989 through 1998 were reviewed, as were bibliographies of review articles and book chapters. Unless otherwise stated, the randomized studies included in this article meet the following criteria: Catheters were inserted into new sites, not old sites over a guidewire; catheter cultures were done by using semiquantitative or quantitative methods; and catheterrelated bloodstream infections were confirmed by microbial growth from percutaneously drawn blood cultures that matched microbial growth from the involved catheter. Authors were contacted directly if these criteria were not stated in published studies. Randomized studies that met these criteria but involved catheter exchange over guidewires into old insertion sites were included only if overwhelming evidence refuted the findings of a single randomized trial involving catheter insertion into new sites only. Any reference to these studies is specifically noted as such in this review. Case-control and cohort studies were included if they investigated issues not addressed in randomized trials regardless of whether they disclosed the site from which blood was drawn for culture or whether catheters were inserted into old sites over guidewires. Case-control or cohort studies are specifically noted as such in this review.
The significance of differences in prevention strategies was determined by using the MantelHaenszel test or the Fisher exact test if the value of a test variable was less than 5. Relative risks, odds ratios, and 95% CIs were calculated by using EpiInfo, version 6 (Centers for Disease Control and Prevention, Atlanta, Georgia). Recommendations for preventive strategies are modified from previously published criteria (12) , and the strength of the evidence is graded as follows: I, evidence from a well-designed meta-analysis of randomized, controlled trials; IIa, evidence from at least one randomized, controlled trial meeting the preceding criteria; IIb, evidence from at least one randomized, controlled trial that allowed catheter exchange over guidewires into old sites; III, evidence from at least one well-designed clinical trial without randomization; and IV, evidence from opinions of authorities in the field based on clinical experience, descriptive studies, or expert committee reports. If more than one type of evidence was available to support a specific recommendation (such as a meta-analysis [I] and an expert committee report [IV] ), only the highest applicable evidence for the recommendation is listed. Recommendations for which results are conflicting reflect the prevailing view, and the highest rated trial based on the preceding criteria is cited.
Preventive strategies are reviewed in the order in which one would approach a patient undergoing intravascular catheterization. Prophylaxis is discussed, followed by procedures surrounding catheter insertion, such as the site of insertion, tunneling of catheters, and antisepsis. Recommendations for maintenance of catheters follows, such as nursing care of catheters and types of available catheter hubs. Antimicrobial-coated or antimicrobial-impregnated catheters are then reviewed.
Preventive Strategies

Intravenous Antimicrobial Prophylaxis
Prophylaxis with vancomycin or teicoplanin during central venous catheter insertion has not been demonstrated to reduce the incidence of catheterrelated bloodstream infection (13-15 [ Table 1] ). Two studies (13, 14) failed to show a difference in early catheter-related bloodstream infection in the antibiotic prophylaxis groups, and in another study (15) , the incidence of bloodstream infection was higher in the prophylaxis group ( Table 1) . Because these studies had small samples, they cannot rule out the possibility of a beneficial effect. Prophylaxis with vancomycin or teicoplanin at insertion of a central venous catheter is not recommended on the basis of the available data [IIa] .
Addition of vancomycin to flush solutions or total parenteral nutrition solutions reduced the risk for catheter-related bloodstream infection with coagulase-negative staphylococci in one study of neonates (odds ratio, 0 [95% CI, 0.0 to 0.7]) (16) . However, Centers for Disease Control and Prevention guidelines recommend against prophylactic use of vancomycin because it is an independent risk factor for acquisition of vancomycin-resistant enterococci (17) .
Prolonged administration of vancomycin-containing dialysate through peritoneal dialysis catheters is associated with peritonitis due to Staphylococcus epidermidis, with markedly reduced susceptibility to vancomycin and exit-site colonization with vancomycin-resistant enterococci (18) . Prolonged use of systemic vancomycin to treat S. aureus infection is associated with development of intermediate resistance to vancomycin (19 -22) and subpopulations of S. aureus with reduced vancomycin susceptibility (22, 23) . Therefore, prevention of intravascular catheter-related infections should not involve vancomycin or other therapeutic agents [IV] . Efforts should be focused on interventions that are not likely to encourage the emergence of antimicrobial resistance, such as maximal barrier precautions.
Warfarin and Heparin Prophylaxis
Several of the different protein components of a thrombus increase adherence of S. aureus, S. epidermidis, and Candida species to catheters (24 -27) . Thrombus formation on indwelling intravascular catheters is associated with catheter-related bloodstream infection (28, 29 activity (33) . Thus, the fewer catheter-related infections associated with heparin use may be due to the preservative, reduced thrombus formation, or both. Prophylactic heparin should be administered to patients with short-term central venous catheters [I] . Three U of heparin per mL in total parenteral nutrition solution, 5000 U every 6 or 12 hours in a flush solution, or 2500 U of subcutaneous low-molecular-weight heparin daily all reduce the risk for catheter-related central venous thrombosis (32) . Heparin treatment should be discontinued if an unexplained decrease in the platelet count is observed, particularly if it is less than 100 000 cells/mL, or a new thrombotic event occurs (34) .
Site of Insertion
No randomized trials have assessed the risk for infection associated with catheter insertion into the subclavian, internal jugular, or femoral vein. However, four prospective, observational studies using multivariate analysis found that risk for infection was significantly increased with insertion into the internal jugular vein compared with insertion into the subclavian vein (6, (35) (36) (37) . Therefore, insertion of a catheter into the subclavian vein is preferred to reduce the risk for infection [III] . However, this risk must be weighed against noninfectious complications associated with subclavian vein insertion (38, 39) . In one prospective, observational study, Cox proportional hazards analysis showed that catheter insertion into the femoral vein was associated with catheter colonization (hazard, 4.2 [CI, 2.0 to 8.8]) (40) . The risk for deep venous thrombosis is higher with femoral vein insertion than with subclavian or internal jugular vein insertion (41) . Therefore, femoral venous catheterization should be limited to circumstances that prevent the use of alternative access sites [III] . (44) . In the studies that showed the greatest benefit from tunneling (42, 43) , potential colonization of catheter hubs was minimized because the catheters were not used for drawing blood. This may have magnified the impact of the intervention by increasing the probability that catheter infections emanate from the insertion site rather than the hub (45) . The restricted manipulation of the catheter hub in these studies contrasts sharply with clinical practice in U.S. hospitals, where central venous catheter hubs are frequently manipulated during blood drawing. Therefore, subcutaneous tunneling of short-term internal jugular or femoral vein catheters is recommended if the catheters are not accessed for drawing blood [IIa] .
Subcutaneously Tunneled Catheters
Cutaneous Antisepsis
In the United States, povidone-iodine is the most widely used antiseptic for cleansing catheter insertion sites (46) . However, in three of four studies, chlorhexidine significantly reduced the incidence of microbial colonization of catheters compared with povidone-iodine (47-50) ( Table 2) . Three studies failed to show a statistically significant difference in catheter-related bloodstream infection when catheters inserted into new sites were cleansed with chlor- hexidine compared with sites cleansed by using povidone-iodine or alcohol (47, 49, 50) (Table 2 ). Limited power in these studies was due to the low incidence of catheter-related bloodstream infection. Alcoholic and aqueous chlorhexidine products are not approved in the United States for use at intravascular catheter insertion sites but are permitted for such use in Canada and Europe. Chlorhexidinecontaining antiseptics should be used, where approved, for skin preparation before catheter insertion [IIa] . Tincture of iodine is superior to povidone-iodine as a cutaneous antiseptic (51, 52) and should be considered for preparation of intravascular sites [IV] .
Sterile Barrier Precautions
Full barrier precautions during insertion of the central venous catheter (sterile gloves, long-sleeved sterile gown, mask, cap, and large sterile sheet drape) reduce the incidence of catheter-related bloodstream infection compared with standard (sterile gloves and small drape) precautions (0.08/1000 and 0.5/1000 catheter-days, respectively; P ϭ 0.02) (53) . These findings are supported by the results of a prospective, observational study (6) . Full barrier precautions should be the standard of care during central venous catheter insertion [IIa] and should be considered during insertion of midline and peripheral artery catheters [IV] .
Catheter Dressing
In two meta-analyses, the risk for central venous catheter-related bloodstream infection did not differ for groups using transparent dressings compared with gauze dressings to cover catheter insertion sites (54, 55), but both analyses included studies with methodologic problems. One study (56) reported a reduced risk for catheter-related bloodstream infection associated with gauze dressings (odds ratio, 0 [CI, 0.0 to 0.8]). No bloodstream infections were reported in another study (57) . No significant difference in catheter-related bloodstream infection was observed between patients with gauze dressings and those with transparent dressings in three large randomized studies that included catheters exchanged over guidewires into old sites (7, 58, 59) . On the basis of all available evidence, the choice of central venous catheter dressing may be a matter of preference and cost [IIb] ; however, gauze dressings are preferred if blood is oozing from the catheter insertion site (58) [IIb].
Ointments
Results of randomized studies of the efficacy of triple antibiotic ointment (polymyxin, bacitracin, and neomycin) applied to catheter insertion sites are indeterminate because of the low number of catheter-related bloodstream infections observed (64) . Prolonged use of mupirocin ointment at catheter insertion sites has been associated with the development of mupirocin resistance (65) , which may reduce the utility of mupirocin for other purposes (66) . Mupirocin ointment may adversely affect the integrity of polyurethane catheters (67, 68) . Therefore, mupirocin ointment should not be applied to catheter insertion sites [IV] .
Povidone-iodine ointment should be applied to the insertion site of hemodialysis catheters [IIa] . Applying povidone-iodine ointment to insertion sites of nontunneled, long-term central venous catheters in immunocompromised patients with heavy S. aureus carriage (such as patients with AIDS [69] or cirrhosis [70] ) should be considered [IV] .
Contamination-Shielded Pulmonary Artery Catheters
Patients who were randomly assigned to have their pulmonary artery catheters self-contained within a thin plastic sleeve that prevented touch contamination had a reduced risk for catheter-related bloodstream infection (odds ratio, 0 [CI, 0.0 to 0.5]) (71) . Therefore, a contamination shield should be used for all pulmonary artery catheters [IIa] .
Catheter Maintenance
Two prospective, observational studies demonstrated that excessive manipulation of central venous catheters independently increases the risk for catheter-related bloodstream infection (37, 72) , probably because of the greater risk for a breach in aseptic technique with multiple manipulations. Inappropriate care of intravascular catheters independently increased the risk for catheter-related bloodstream infection in another observational study (73 Two trials assessed specialized care provided by trained nursing teams that assured stringent adherence to aseptic technique during insertion of peripheral catheters and catheter dressing changes (80, 81) . No bloodstream infections occurred in one study (80) . In the other study (81) , catheter-related bloodstream infection was reduced in the specialized care group (odds ratio, 0 [CI, 0.0 to 0.6]). Specialized nursing care significantly reduced phlebitis in both studies. Specialized nursing teams caring for patients with short-term peripheral venous catheters should be used to reduce the risk for phlebitis and catheter-related bloodstream infection, particularly at institutions with an increased incidence of these events [IIa] . Specialized nursing teams should also be used to reduce catheter-related infections in patients receiving total parenteral nutrition [IV] .
The results of a meta-analysis (82) are inconclusive with regard to any benefit toward reduction of catheter-related bloodstream infection by routine replacement of central venous catheters by using guidewire exchange (relative risk, 1.7 [CI, 0.9 to 3.3]). Routine replacement of central venous catheters is not indicated [I] as long as the integrity of the catheter polymer is stable for the expected use of the catheter and the duration of catheterization (83) .
Intravascular catheters may remain in place long after their intended use (84) , increasing the risk for catheter-related bloodstream infection. Physicians and nurses should assess patients' need for intravascular catheters, and all other temporary foreign bodies, on a daily basis. These devices should be removed as soon as possible after their intended use [IV] (85).
Injection Hub and Connection Port
Catheter hubs and sampling ports should be disinfected before they are accessed [IV] (8 -10). Alcohol, povidone-iodine, and chlorhexidine are effective (86, 87) but are only slightly more effective than saline because premoistened cotton swabs physically remove most pathogens from catheter hubs (86) .
In one trial (88), a hub containing an antiseptic chamber filled with iodinated alcohol reduced the risk for central venous catheter-related bloodstream (relative risk, 0.2 [CI, 0.1 to 0.7]). This hub is available in Europe but not the United States. Another trial assessed the efficacy of a sponge saturated with povidone-iodine housed within a plastic casing and fitted around the catheter hubs (89) . It reduced the incidence of catheter-related bloodstream infection from 24% to 0% (P ϭ 0.02). This device is available in the United States but not in Europe. In both trials, catheters were in place for approximately 2 weeks. Greater catheter hub manipulation increases the risk for contamination (90) . During prolonged catheterization, catheter hubs are accessed multiple times, increasing the likelihood that catheter-related bloodstream infection emanates from colonized hubs rather than the insertion site (91) . Either of these two specialized hubs should be considered for patients without iodine allergies who require central venous catheterization for approximately 2 weeks [IIa] or possibly longer. These devices may benefit ICU patients whose central venous catheters are heavily manipulated but will be in place for a shorter duration [IV] .
Many needleless systems are available for use with intravascular catheters. Several case-control and cohort studies have demonstrated an increased risk for catheter-related bloodstream infection with these devices (92) (93) (94) (95) (96) (97) (98) (99) (100) (101) (102) . This may reflect suboptimal design of the device (93, 96) , infrequent replacement of the needleless device or the end caps covering the device (94, 97, 99) , contamination of the device with water-borne gram-negative bacilli during bathing or other activities (96, 98, 100) , or selfadministered intravenous infusions (98) . In vitro experiments have shown that proper disinfection of needleless system injection sites prevents microbial transfer from the hub to the intraluminal fluid path of catheters (100 -102) . In a crossover clinical trial (103), use of a needleless system after adequate training did not increase the risk for catheter-related bloodstream infection. In a larger trial, a needleless system was independently associated with reduced contamination of infusate (104) . To prevent intravascular catheter-related bloodstream infection associated with needleless systems, the device and the end cap (if present) should be changed regularly in accordance with manufacturers' guidelines, the surface of the device should be adequately disinfected before it is accessed (for example, by using an isopropyl alcohol-saturated pad), and special care should be taken to reduce direct contact with nonsterile water [III] .
Inline Filters
Inline 0.22-m filters in intravenous tubing reduce the risk for phlebitis (105) . There are no adequate studies showing that filters reduce the risk for catheter-related bloodstream infection. Inline filters are not recommended for prevention of these infections [IV].
Antimicrobial-Coated or Impregnated Catheters and Cuffs
Antimicrobial-impregnated or antimicrobial-coated devices and cuffs are important additions to the group of preventive strategies. Most pulmonary artery and umbilical artery catheters are heparin-bonded with benzalkonium chloride. The benzalkonium chloride provides the catheters with short-lived antimicrobial activity (106) . Benzalkonium chloride-coated pulmonary artery catheters should be used because they may prevent catheter-related infections [IV] .
A silver-impregnated subcutaneous collagen cuff attached to a central venous catheter acts as a tissueinterface barrier. The findings of two studies of short-term catheter-related bloodstream infections associated with use of this commercially available cuff are inconclusive because of the small number of catheter-related bloodstream infections observed (107, 108) (Table 3 ). In the combined trials, with dwell times of 20 days or longer, use of this cuff did not reduce the incidence of catheter-related bloodstream infection (109 -111) ( Table 3) . Extrusion of the silver cuff from the catheter tunnel tract to the skin and minimal subcutaneous anchorage of tunneled, silver-cuffed central venous catheters have been observed, possibly because of a cytotoxic effect of the silver (112) . On the basis of all available evidence, use of this device is not recommended with short-term [IIa] or long-term [IIa] catheters.
The efficacy of catheters impregnated with chlorhexidine and silver sulfadiazine on the outer surface was the subject of a meta-analysis (113) . The Mantel-Haenszel method was used in the present review to estimate a summary measure of the effect of this device on catheter-related bloodstream infections by combining the results from six of eight prospective studies of short-term (less than 2 weeks) central venous catheterization (8, 114 -120) (Table 4 ). This analysis demonstrates that short-term use of a catheter impregnated with chlorhexidine and silver sulfadiazine reduced the risk for central venous catheter-related bloodstream infection (Mantel-Haenszel weighted relative risk, 0.4 [Greenland-Robins CI, 0.2 to 0.8]). One study (121) failed to show a difference in central venous catheter-related bloodstream infection with use of this catheter for a more prolonged dwell time ( Table 4) . Use of this catheter should reduce cost in settings in which the incidence of bloodstream infection caused by use of short-term central venous catheters is greater than 3.3 per 1000 catheter-days (8) .
On the basis of a multivariate sensitivity analysis, use of this catheter should lead to a cost saving of $68 to $391 per catheter (122) . The currently marketed chlorhexidine-silver sulfadiazine-impregnated catheter is not effective for catheters in place for an average of 3 weeks (121) ( Table 4 ). This finding * Data from randomized studies that used quantitative or semi-quantitative catheter culture methods and percutaneously drawn blood cultures or Ͼ10 3 colony-forming units of microbial growth/mL of blood collected through the catheter to define bloodstream infection in catheters inserted into a new site (without antimicrobial ointment applied to the site) rather than over a guidewire into an old site.
probably reflects reduced antimicrobial activity of the catheter over time (116, 121) and a lack of protection from microbes invading the luminal surface of the catheter from contaminated hubs. Resistance to the chlorhexidine-silver sulfadiazine catheter has not been demonstrated in clinical studies. In vitro studies designed to induce microbial resistance to chlorhexidine have been successful (123) . These experiments were done in the absence of silver sulfadiazine, with bacteria not usually associated with catheter-related infections and under conditions that differ from the clinical conditions in which the chlorhexidine-silver sulfadiazine catheter is used. There are reports, predominantly in Japan, of anaphylactic reactions to the chlorhexidine component of this catheter (124) . As of 30 December 1999, no such reactions were reported to the U.S. Food and Drug Administration (Freedom of Information Inquiry). Use of central venous catheters impregnated with chlorhexidine and silver sulfadiazine should be considered when catheterization is expected to last less than 2 weeks and when the rate of infection is high despite adherence to other strategies, such as maximal barrier precautions [I] . Adverse reaction associated with this or any other device should be reported to the U.S. Food and Drug Administration's MedWatch program (www.fda.gov/medwatch) and the Centers for Disease Control and Prevention (www.cdc.gov).
Use of commercially available central venous catheters impregnated intraluminally and extraluminally with minocycline and rifampin reduces the risk for catheter-related bloodstream infection compared with the currently available chlorhexidine-silver sulfadiazine-impregnated catheter (relative risk, 0.1 [CI, 0.0 to 0.6]) (125) . Resistance to minocycline and rifampin impregnated on catheter surfaces has not been demonstrated in clinical studies, but population analysis (22, 23) was not used to determine whether subpopulations of skin microbes develop resistance after prolonged exposure to this antibiotic-impregnated catheter. One in vitro study suggested that use of catheters impregnated with minocycline and rifampin may lead to development of resistance to these agents (126) . However, use of these devices may reduce the use of systemic antibiotics, such as vancomycin. Use of central venous catheters impregnated with minocycline and rifampin should be considered when the rate of bloodstream infection related to use of short-term central venous catheters is high despite use of preventive strategies that do not incorporate agents otherwise used for systemic antimicrobial therapy [IIa] .
Current recommendations for the prevention of catheter-related bloodstream infection are listed in Table 5 .
The Future
Over the past 25 years, much has been learned about catheter-related infections and their prevention. However, additional adequately powered randomized studies with appropriate microbiological methods are needed.
A study of covalently linked heparin on the surface of central venous catheters to reduce the risk Gene products of an identified operon mediate the S. epidermidis autoaggregation and biofilm formation so commonly encountered on the surface of colonized intravascular catheters (131) . Blocking the expression of this operon may prevent adherence of S. epidermidis to the catheter surface. Antibodies that block the fibronectin-binding protein adhesin of S. aureus have been developed (132) . Coating future catheters with similar antiadhesin molecules may thwart S. aureus infection. Quorum sensing among microbes is necessary for the maturation of biofilm (133) . A better understanding of this form of microbial communication may lead to the development of chemical messengers that block biofilm formation.
Future prospects for the prevention of foreign body infections are bright. Our expanding knowledge of the molecular pathogenesis of catheter infections will undoubtedly guide us in the continued struggle against microbial colonization of tomorrow's catheters. From Rhode Island Hospital and Brown University School of Medicine, Providence, Rhode Island.
